middle.news
Imugene Gains FDA Nod to Advance Azer-cel into Pivotal Study
9:09am on Monday 8th of December, 2025 AEDT
•
Healthcare
Read Story
Imugene Gains FDA Nod to Advance Azer-cel into Pivotal Study
9:09am on Monday 8th of December, 2025 AEDT
Key Points
FDA feedback supports pivotal study initiation for azer-cel
Imugene to host investor webinar detailing regulatory progress
Azer-cel targets CD19 for blood cancer treatment
Pipeline includes oncolytic virotherapy CF33 for solid tumors
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imugene (ASX:IMU)
OPEN ARTICLE